FDA approves higher max daily dose of FIRDAPSE for LEMS to 100 mg

CATALYST PHARMACEUTICALS, INC.

FDA approved sNDA increasing FIRDAPSE max daily dose from 80 mg to 100 mg for adults and peds >45 kg with LEMS.
FIRDAPSE is the only U.S.-approved treatment for LEMS; expanded dosing offers greater treatment flexibility.
CEO Richard Daly states approval will have meaningful impact on LEMS patient outcomes.
Catalyst Pathways patient support program available for eligible patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.